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INTERNATIONAL REGULATION OF 
PHARMACEUTICALS: A WHO INTERNATIONAL 
CODE OF CONDUCT FOR THE MARKETING 
OF PHARMACEUTICALS? 
I. INTRODUCTION 
The international pharmaceutical trade is important to both 
exporting and importing countries. Exporting countries are con-
cerned with maintaining and further expanding their foreign phar-
maceutical markets.1 Importing countries, especially developing or 
less developed countries (LDC's),2 are concerned with the price and 
quality of drugs that they import.3 Poor and newly independent 
states• that have no pharmaceutical industry of their own are the 
most vulnerable in the international pharmaceutical trade.5 They 
must rely on exports from the more developed nations. The 
likelihood of these LDC's importing drugs of unacceptable quality 
is high6 because they usually buy at the lowest prices available and 
have no reliable quality control systems of their own.7 These LDC's 
are also greatly disadvantaged in their negotiations with the 
multinational corporations (MNC's)8 that manufacture phar-
maceutical products.9 The World Health Organization (WHO) has 
1. D. KAY, THE INTERNATIONAL REGULATION OF PHARMACEUTICAL DRUGS 23 (1976). 
2. Stanley, International Codes of Conduct for MNC's: A Skeptical View of the Pro-
cess, 30 AM. U. L. REV. 973, 974 (1981). 
3. KAY, supra note l, at 37. 
4. The newly independent states of Africa and Asia are examples. These states share 
serious health needs and create a large market for pharmaceutical products. They have little 
foreign exchange available to purchase quality drug products and few inspectors to check 
drug quality. Id. 
5. Id. 
6. Id. 
7. Id. 
8. "MNC" is the most common term used in the United States to describe companies 
that operate in many countries. Other terms include: transnational enterprise (TNE), multina-
tional enterprise (MNE), and transnational corporation (TNC). Stanley, supra note 2, at 973 n.l. 
For further information concerning the characteristics of MNC's, see Vagts, The Global 
Corporation and International Law, 6 J. INT'L L. & ECON. 247, 247-48 (1972); Behrman, The 
Multinational Enterprise: Its Ini tiatives and Governmental Reactions, id. at 215, 216-20; Note, 
Taming the Transnationals: An Examination of Structural Solutions to Regulation of Trans-
national Enterprise and the Theoretic Problem of Sovereignty, 7 W. ST. U.L. REv.187, 188-89 
(1980); Von Mehren & Gold, Multinational Corporations: Conflicts and Controls, 11 STAN. J. 
INT'L STUD. l, 1-4 (1976). 
9. Note, International Regulation of Pharmaceuticals: The Role of the World Health 
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adopted international regulatory programs10 that attempt to rescue 
LDC's from the dangers surrounding the purchase of low quality 
pharmaceuticals.11 Both developed and developing countries, 
however, have expressed their dissatisfaction with the application12 
and adequacy of these programs.13 
This Note will discuss the current major programs in the in-
ternational regulation of pharmaceuticals. Discussion will also focus 
on the recent proposals for regulation, with particular emphasis on 
an international code of conduct for the marketing of phar-
maceuticals. After examining how a code of conduct can become 
customary international law, this Note predicts the likelihood of 
the adoption and the legal effect of an international code for the 
marketing of pharmaceuticals. Finally, this Note suggests a solu-
tion for LDC's that implicates product liability law. 
II. PAST EFFORTS IN THE INTERNATIONAL 
REGULATION OF PHARMACEUTICALS 
Although other governmental and nongovernmental inter-
national organizations14 participate in the international regulation 
of drug products, the World Health Organization (WH0)15 is the prin-
Organization, 23 VA. J. INT'L L. 331, 332 (1983). 
For an analysis of LDC's reaction to MN C's in general, see Note, Multinational Cor-
porations and Lesser Developed Countries-Foreign Investment, Transfer of Technology, and 
the Paris Convention: Caveat Investor, U. DAYTON L. REv.105, 109-13 (1980); Behrman, supra 
note 8, at 224-28; Von Mehren & Gold, supra note 8, at 4-8; Vagts, supra note 8, at 253-54. 
10. See, e.g., Good Practices in the Manufacture and Quality Control of Drugs, World 
Health Organization, Official Records, No. 226, Annex 12 (1975); Certification Scheme on the 
Quality of Pharmaceutical Products Moving in International Commerce, id.; Action Pro-
gramme on Essential Drugs, World Health Assembly, Report by the Executive Board Ad 
Hoc Committee on Drug Policies on Behalf of the Executive Board, W.H.O. Doc. A35/7 (1982). 
11. KAY, supra note l, at 37-38. 
12. Complaints concerning the application of these programs include expense, uneven 
national inspection, and lack of support from pharmaceutical MNC'S. Id. at 38-39, 45, 46-47. 
13. Complaints concerning the adequacy of these programs stem from the fact that 
the programs do not cover all aspects of drug manufacture and distribution. For an exam-
ple of one program which does not cover packing, transit, shelf life, and storage, see id. at 47. 
14. For a list of various governmental and nongovernmental organizations which par-
ticipate in pharmaceutical regulation, see id. at 33. 
For an example of recent governmental participation, see Wassermann, Annapolis Con-
ference of Drug Registration Authorities, 15 J.W.T.L. 363 (1981). 
15. WHO is a specialized agency established within the terms of article 57 of the 
Charter of the United Nations. CONSTITUTION OF THE WORLD HEALTH ORGANIZATION, in BASIC 
DOCUMENTS, preamble (33d ed. 1983) [hereinafter cited as WHO CONST]. WHO's objective is 
the "attainment by all peoples of the highest possible level of health." Id. art. 1. 
WHO is composed of the World Health Assembly (WHA), the Executive Board, and 
the Secretariat. Id. art. 9. WHA, which consists of all the members of WHO each represented 
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cipal assemblage dealing with the regulation of pharmaceuticals. 
WHO's efforts in drug regulation began in the 1950's.16 WHO did 
not, however, develop its major programs until late in the 1960's 
and through the 1970's.17 These major programs are: Good Prac-
tices in the Manufacture and Quality Control of Drugs,18 Certifica-
tion Scheme on the Quality of Pharmaceutical Products Moving in 
International Commerce,19 and Action Programme on Essential 
Drugs.20 
A. GOOD PRACTICES IN THE MANUFACTURE AND QUALITY 
CONTROL OF DRUGS 
WHO intended that Good Practices in the Manufacture and 
by up to three delegates, determines WHO policy. Id. arts. 10, 11, 18(a). It has the authority 
to adopt conventions, agreements, and certain regulations and make recommendations to 
member countries. Id. arts. 19, 21, 23. The Executive Board consists of thirty persons each 
elected to serve for three years. Id. arts. 24, 25. It gives effect to the decisions and policies 
of WHA. Id. art. 28(a). The Secretariat is composed of the Director-General, who is appointed 
by WHA, and any technical and administrative staff that WHO may need. Id. arts. 31, 32. 
The Director-General is the chief technical and administrative officer of WHO. Id. art. 31. 
Although WHO headquarters is located in Geneva, a great amount of its work occurs 
in its six regional offices or organizations. For the composition and functions of the regional 
organizations, see id. arts. 44-54. 
For further information on the background and work of WHO, see F. BROCKINGTON, 
WORLD HEALTH 149-74 (3d ed.1975); Gutteridge, The Worl,dHealth Organization: Its Scope and 
Achievements, 37 TEMP. L.Q. 1 (1963); Note, International Regulation of Pharmaceuticals: The 
Role of the World Health Organization, 23 VA. J. INT'L L. 331, 340-46 (1983) [hereinafter cited 
as International Regulation]. 
16. KAY, supra note 1, at 35. 
In 1951, the Executive Board called for a meeting of various countries' drug authorities 
to discuss uniform methods for the control of drugs in international commerce. E.B. Res. 
7.R79 (1951), reprinted in 1 World Health Organization, HANDBOOK OF RESOLUTIONS AND DECI-
SIONS OF THE WORLD HEALTH ASSEMBLY AND THE EXECUTIVE BOARD 130 (1973) [hereinafter 
cited as 1973 HANDBOOK OF RESOLUTIONS]. 
17. WHA requested the development of Good Practices in the Manufacture and Quality 
Control of Drugs in 1967. W.H.A. Res. 20.34 (1967) 11973 HANDBOOK OF RESOLUTIONS, supra 
note 16, at 132. 
WHA urged member states to adopt the Certification Scheme on the Quality of Phar-
maceutical Products Moving in International Commerce in 1969. W.H.A. Res. 22.50 (1969) 
id. at 133. 
In January 1978, the Executive Board appointed an ad hoc committee to consider the 
feasibility of the Action Programme on Essential Drugs. World Health Organization, Of 
ficial Records, No. 244, 30 (1978). 
18. World Health Organization, Official Records, No. 226, Annex 12 (1975) [hereinafter 
cited as GMP]. 
19. World Health Organization, Official Records, No, 226, Annex 12 (1975) [hereinafter 
cited as Certification Scheme]. 
20. World Health Assembly, Action Programme on Essential Drugs: Report by the 
Executive Board Ad Hoc Committee on Drug Policies on Behalf of the Executive Board, 
W.H.O. Doc. A35/7 (1982) [hereinafter cited as APED]. 
3
et al.: International Regulation of Pharmaceuticals: a Who International
Published by SURFACE, 1984
124 Syr. J. lnt'l L. & Com. [Vol. 11:121 
Quality Control of Drugs (Good Manufacturing Practices Act or 
GMP)21 have three major purposes: 
(1) to serve as guidelines for drug manufacturers in their own 
quality control efforts; 
(2) to serve as guidelines for national health authorities in their 
monitoring of drug manufactures and in drafting national regula-
tions; and 
(3) to serve in the case of imported drugs as a set of criteria by 
which the importing country ... is assured that the drugs it im-
ports have been properly manufactured in the country of origin.22 
G MP serves as a guideline in many major phases of the drug 
manufacturing process.23 It first sets forth educational24 and prac-
21. WHO began work on GMP in 1967. In May 1967, WHA requested the Director-
General to formulate principles for quality control procedures to be used in good manufac-
turing practice. W.H.A. Res. 20.34 (1967) 1 1973 HANDBOOK OF RESOLUTIONS, supra note 16, 
at 132. Between 1967 and 1969, the Director-General, in consultation with the WHO Expert 
Committee on Specifications for Pharmaceutical Preparations, drafted recommendations on 
GMP. KAY, supra note 1, at 42. For the unrevised GMP, see World Health Organization, Of 
ficial Records, No. 176, Annex 12 (1969). In July 1969, WHA recommended that member 
states adopt the unrevised GMP. W.H.A. Res. 22.50 (1969) 11973 HANDBOOK OF RESOLUTIONS, 
supra note 16, at 133. In May 1970, WHA requested member states to inform the Director-
General of their steps taken to implement the unrevised GMP and to submit suggestions 
for improvement on the text. W.H.A. Res. 23.45 (1970) id. The WHO Expert Committee on 
Specifications for Pharmaceutical Preparations received the replies of member states and 
recommended textual changes. World Health Organization, Official Records, No. 197, 148 
(1971). In 1974, the Committee adopted a final revised text. Id., No. 221, 119 (1974). In May 
1975, WHA adopted the revised text of GMP and recommended that member states apply 
the revised provisions. W.H.A. Res. 28.65 (1975) 2 World Health Organization, HANDBOOK 
OF RESOLUTIONS AND DECISIONS OF THEW ORLD HEALTH ASSEMBLY AND THE EXECUTIVE BOARD 
114 (5th ed. 1983) [hereinafter cited as 1983 HANDBOOK OF RESOLUTIONS]. For the revised GMP 
text, see GMP, supra note 18. 
22. KAY, supra note 1, at 42. 
23. GMP, supra note 18, § l, para. 4. 
GMP defines "manufacturing" as "[a]ll operations involved in the production of a drug, 
including processing, compounding, formulating, filling, packaging, and labelling." Id. § 2. 
Id. 
GMP defines "drug" as 
[a]ny substance or mixture of substances that is manufactured, sold, offered for 
sale, or represented for use in (1) the treatment, mitigation, prevention, or diagnosis 
of disease, an abnormal physical state, or the symptoms thereof in man or animal; 
or (2) the restoration, correction, or modification of organic functions in man or 
animal. 
24. "Experts ... should possess the qualifications of scientific education and practical 
experience required by national legislation." Id. § 3, para. 1. This section of GMP also specifies 
appropriate courses of study for an expert's education. Id. 
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tical experience25 qualifications for experts supervising the manufac-
ture and quality control of drugs.26 GMP next describes suitable 
premises for the manufacture27 and storage28 of drug products. It 
also requires that manufacturing equipment be designed and main-
tained to facilitate use and minimize contamination.29 GMP provides 
for sanitation30 by suggesting the availability of a written sanita-
tion program.31 Starting materials32 should be properly labeled, 
stored, sampled, and tested.33 The guidelines for manufacturing 
operations are the most extensive.34 They include requirements for 
personnel,35 sanitation,36 equipment and containers,37 manufacturing 
procedure documents,38 and batch manufacturing records.39 GMP 
makes suggestions for proper packaging and labeling of drugs, in-
cluding information to be properly displayed on labels.40 It also sets 
forth the duties of the quality control department and laboratory.41 
Finally, GMP provides for the adequate maintenance of distribu-
tion records42 and the proper receipt of and response to complaints 
regarding drug quality.43 
WHO adopted these GMP provisions as recommendations 
because it intended GMP to serve as a guideline.44 Recommenda-
25. GMP suggests that experts undergo a preparatory period during which they 
exercise their duties under professional supervision. Id. 
26. Id. 
27. Id. § 4.1. 
28. Id. § 4.2. 
29. Id. § 5. 
30. GMP does not define "sanitation," but it does specify that the manufacturing 
premises should be "clean and free from accumulated waste, orderly, and free from vermin." 
Id. § 6, para. 1. 
31. Id. § 6. 
32. GMP defines "starting materials" as "(aJll substances, whether active or inactive 
or whether they remain unchanged or become altered, that are employed in the manufac-
ture of drugs." Id. § 2. 
33. Id. § 7. 
34. Id. § 8. 
35. Id. § 8.4. 
36. Id. §§ 8.1, 8.3. See also su:pra note 30. 
37. Id. § 8.2. 
38. Id. § 8.5. 
39. Id. §§ 8.6, 8.7. 
GMP defines "batch" as "[a] quantity of any drug produced during a given cycle of 
manufacture." Id. § 2. 
40. Id. § 9. 
41. Id. § 10. 
42. Id. § 12. 
43. Id. § 13. 
44. KAY, supra note 1, at 44. 
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tions of the World Health Assembly (WHA)45 are not legally binding 
on member states.46 In addition to GMP's nonbinding effect, WHO 
intended the provisions to be somewhat ambiguous.47 This ambiguity 
facilitates compliance by member countries, especially those 
developing countries moving into pharmaceutical production.48 As 
these GMP recommendations can only be enforced by those national 
authorities that choose to adopt them,49 the developing countries 
prefer a more reliable method of ensuring quality drug imports.50 
In order to allay the concerns of developing countries; WHO pur-
sued a certification scheme for pharmaceutical products.51 
B. CERTIFICATION SCHEME ON THE QUALITY OF PHARMACEUTICAL 
PRODUCTS MOVING IN INTERNATIONAL COMMERCE 
WHO intended that the Certification Scheme on the Quality 
45. "The Health Assembly shall have authority to make recommendations to Members 
with respect to any matter within the competence of the Organization." WHO CONST, supra 
note 15, art. 23. 
WHA also has "authority to adopt conventions or agreements with respect to any 
matter within the competence of the Organization." Id. art. 19. Each member must notify 
the Director-General within eighteen months of action taken to accept the convention or 
provide the Director-General with reasons for its non-acceptance. Id. art. 20. 
WHA may also adopt regulations concerning "standards with respect to the safety, 
purity and potency of biological, pharmaceutical and similar products moving in international 
commerce .... " Id. art. 21. WHA regulations come into force for all member states except 
for those that notify the Director-General of their rejections or reservations within a specified 
time. Id. art. 22. 
These procedures for the adoption of conventions, agreements, and regulations have 
been viewed as a great improvement on the slow and uncertain ratification procedures 
employed by other agencies. Codding, Contributions of the World Health Organization and 
the International Civil Aviation Organization to the Development of International Law, 1965 
AM. Soc·y INT'L L. PROC. 147-48. 
46. KAY, supra note 1, at 44. 
47. For example, GMP recommends that experts have the "scientific education and 
practical experience required by national legislation." GMP, supra note 18, § 3, para. 1. It 
also recommends that "[m]anufacturing premises should be maintained in accordance with 
sanitary standards issued by the appropriate health authority." Id. § 6. These recommen-
dations leave extensively different national policies untouched. KAY, supra note l, at 44. 
GMP is also ambiguous because it fails to define major terms, such as "sanitation." 
See supra note 30. GMP also states that an "adequate number of technically trained person-
nel should be available to carry out the manufacturing and quality control operations . 
. . . " GMP, supra note 18, § 3, para. 3. It fails, however, to specify what constitutes an "ade-
quate number." 
48. Developing states lack the regulatory facilities of the more developed nations. As 
these developing states slowly move into pharmaceutical production, they will rely on GMP 
in setting their national policies. These countries will use GMP as a guideline in drafting 
their own GMP codes. KAY, supra note 1, at 45. 
49. Id. 
50. Id. 
51. Id. 
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of Pharmaceutical Products Moving in International Commerce (Cer-
tification Scheme)52 serve two major purposes. The Certification 
Scheme is to assure importing countries that the imported drug 
product is "authorized for sale or distribution within the exporting 
Member State .... "53 It also assures importing countries that the 
manufacturer complies with GMP.54 
The Certification Scheme provides for certification of phar-
maceutical products55 and exchange of information concerning defec-
tive products.56 Upon the request of an importing country, the com-
petent authority 57 of the exporting country certifies a phar-
maceutical product by issuance of a Certificate of Pharmaceutical 
Products.58 The Certificate of Pharmaceutical Products certifies that 
the product is authorized for sale within the exporting state and 
that the manufacturer complies with GMP.59 The competent health 
authority of the importing country then decides whether to allow 
sale or distribution of the product within its borders.60 The manufac-
52. The development of the Certification Scheme closely paralleled the development 
of GMP. In July 1969, WHA recommended that member states adopt the then unrevised 
Certification Scheme. W.H.A. Res. 22.50 (1969) 11973 HANDBOOK OF RESOLUTIONS, supa note 
16, at 133. For the text of the unrevised Certification Scheme, see World Health Organiza-
tion, Official Records, No.176, Annex 12 (1969). In May 1970, WHA requested member states 
to inform the Director-General of their steps taken to implement the Certification Scheme 
and to submit suggestions for improvement on the text. W.H.A. Res. 23.45 (1970) 1 1973 
HANDBOOK OF RESOLUTIONS, supa note 16, at 133. In 1972, WHA received several comments 
from member states concerning technical and administrative aspects of the Certification 
Scheme. World Health Organization, Official Records, No. 205, 153 (1973). The exporting coun-
tries and pharmaceutical manufacturers resisted the original requirements for batch cer-
tification. They argued that batch certification would be expensive and surpass the capabilities 
of the national quality control facilities. KAY, supa note l, at 46. In 1973, WHA prepared 
a draft revised Certification Scheme, which corrected many of the difficulties with batch 
certification. WHA adopted the revised Certification Scheme in May 1975. W.H.A. Res. 28.65 
(1975) 2 1983 HANDBOOK OF RESOLUTIONS, supra note 21, at 114. For the revised Certification 
Scheme text, see supra note 19. By the end of 1981, seventy-one member states had agreed 
to participate in the Certification Scheme. BIENNIAL REPORT OF THE DIRECTOR-GENERAL, THE 
WORK OF WHO 1980-1981, 86 (1982) [hereinafter cited as BIENNIAL REPORT]. 
53. Certification Scheme, supra note 19, Part I § 3(a). 
54. Id. Part I § 3(b). 
55. Id. Part I. 
A pharmaceutical product is "any medicine in its finished dosage form, intended for 
human use, that is subject to control by legislation in the exporting Member State and in 
the importing Member State." Id. Part I § 1. 
56. Id. Part II. 
57. The Certification Scheme does not define "competent authority," which is used 
throughout the recommendation. 
58. Certification Scheme, supra note 19, Part I § 2. 
59. Id. Part I § 3(a), (b). 
60. Id. Part I § 2. 
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turer or health authority of the exporting country may also issue 
certificates to individual batches of products.61 
Upon its discovery of a quality defect62 in imported drug prod-
ucts, the importing country is to notify the exporting country's 
authority about the incident with a "request to institute inquiries."63 
Conversely, the exporting country's health authority should notify 
the importing country's authority about any serious quality defects 
it may discover.64 Each participating member state must police its 
own health authority and pharmaceutical industry to ensure that 
its health authority employs proper testing procedures,65 that its 
drug industry complies with GMP requirements,66 that its authority 
conducts appropriate investigations,67 and that its health authority 
inspectors are appropriately qualified.68 
As with GMP, WHO adopted the Certification Scheme as a 
recommendation, wholly nonbinding on member states.69 Some 
authorities view this scheme as an important first step in the direc-
tion toward the international registration of pharmaceuticals.70 
Other authorities, however, have identified certain problems that 
the scheme does not address. 71 
A major problem is that some countries72 do not require 
registration of drugs produced for export. These countries cannot 
attest that their products are authorized for domestic sale.73 Addi-
61. Id. Part I § 4. 
62. The Certification Scheme does not define "quality defect," but it does state that 
notification is necessary when the quality defect is "considered to be of a serious nature 
... not attributable to local conditions and circumstances .... " Id. Part II § 2. 
63. Id. 
64. Id. 
65. Id. Part III § 2(a). 
66. Id. Part III § 2(b). 
67. Id. Part III § 2(c). 
68. Id. Part III § 2(d). 
69. See supra note 45. 
70. Wassermann, WHO Pharmaceutical Certification Scheme, 10 J.W.T.L. 185, 187 (1976). 
71. KAY, supra note l, at 47. 
72. For example, the United Kingdom, Switzerland, France, and Italy. Drugs produced 
for export in these major drug exporting states are exempted from national regulatory re-
quirements. Id. at 46. 
73. Id. at 47. 
The United States can attest that its drug products are authorized for domestic sale. 
United States drug establishments which manufacture, prepare, or process drugs are "re-
quired to register and to submit a list of every drug in commercial distribution .... " 21 
C.F.R. § 207.20(a) (1984). Furthermore, "[e]very foreign drug establishment whose drugs are 
imported ... into the United States must also comply with these drug listing requirements." 
Id. § 207 .40(a). 
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tionally, quality inspection by national authority is irregular and 
may not be a government responsibility.74 The Certification Scheme 
fails to make provision for transportation, storage, or shelf life which 
may cause quality defects in drug~.75 WHO, however, did not cease 
its efforts with the Certification Scheme, but moved forward to 
establish a more comprehensive program for regulation.76 
C. ACTION PROGRAMME ON ESSENTIAL DRUGS 
In February 1981, WHO established the Action Programme on 
Essential Drugs (APED),77 a more comprehensive program for 
regulation, which includes the Certification Scheme. APED assists 
nations in "increasing the availability and utilization of drugs at 
the lowest possible cost for primary health care, particularly 
through the formulation and implementation of national drug 
policies."78 
APED enumerates the steps necessary for the elimination and 
prevention of disease through drugs. 79 The first step is to deter-
mine the health care needs of a country,80 choose the drugs that 
74. KAY, supra note 1, at 47. 
75. Id. 
76. APED, supra note 20. 
77. Id. 
WHA first envisioned APED in May 1975, when it requested the Director-General 
"to develop means by which the Organization can be of greater direct assistance to Member 
States in ... advising on the selection and procurement ... of essential drugs of established 
quality corresponding to their national health needs .... " W.H.A. Res. 28.66 (1975) 2 1983 
HANDBOOK OF RESOLUTIONS, supra note 21, at 110. 
In January 1978, the Executive Board also called upon the Director-General to "ap-
peal to governments and the pharmaceutical industry to participate in WHO's action pro-
gramme of technical cooperation aimed at making available to governments of the less 
developed countries essential drugs and vaccines .... " E.B. Res. 61.Rl 7 (1978) id. at 111. 
The Executive Board also appointed an ad hoc committee to consider the feasibility of a 
formal Action Programme on Essential Drugs. World Health Organization, Official Record, 
No. 244, 30 (1978). 
In May 1978, WHA further urged the Director-General to "submit ... a comprehen-
sive action programme ... aimed at fostering technical cooperation among developing coun-
tries .... " W.H.A. Res. 31.32 (1978) 2 1983 HANDBOOK OF RESOLUTIONS. supra note 21, at 112. 
In May 1979, WHA again requested the Director-General "to establish a special programme 
on essential drugs ... " and urged member states "to participate in the action programme 
on essential drugs .... " W.H.A. Res. 32.41 (1979) id. 
In conformity with the preceding resolutions, WHO formally established APED in 
February 1981. BIENNIAL REPORT, supra note 52, at 88. For a discussion of regional participa-
tion in APED~ see id. at 88-90. 
78. BIENNIAL REPORT, supra note 52, at 88. 
79. APED, supra note 20, at 6, para. 27, cited in International Regulation, supra note 
15, at 351. 
80. Id. 
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are essential to these health care needs,81 and estimate the quan-
tities of drugs required.82 The second step is to assist a country in 
developing an adequate drug supply system.83 The third step is to 
guarantee the proper use of drugs by providing information to users 
and suppliers.84 
APED calls upon WHO to coordinate international health and 
technical matters. 85 WHO is to induce cooperation among govern-
ments, international organizations,86 pharmaceutical industries,87 and 
experts.88 WHO is also to develop international policies, provide 
guidelines for national drug policies, and distribute information con-
cerning drug qualities, prices, and suppliers.89 
APED is thus a voluntary program of international coopera-
tion for the international quality control of drugs. Many experts, 
however, have proposed that WHO play a more direct role in the 
international regulation and quality control of drugs.90 
81. Id. 
WHA devised a model list of essential drugs, which was the basis for cooperation with 
member states. BIENNIAL REPORT, supra note 52, at 88. By the end of 1981, more than forty 
countries had developed a national list. Id. 
82. APED, supra note 20, at 6, para. 27, cited in International Regulation, supra note 
15, at 351. 
Many member states cooperated in the quantification of drug needs. BIENNIAL REPORT, 
supra note 52, at 88. 
83. This step includes the procurement of drugs at affordable prices and the improve-
ment of storage, quality control, ~nd distribution facilities. APED, supra note 20, at 6, para. 
27, cited in International Regulation, SJA,pra note 15, at 351-52. 
84. APED, supra note 20, at 6, para. 27, cited in International Regulation, supra note 
15, at 352. 
In 1980 and 1981, WHO proposed the preparation of information sheets on essential 
drugs aimed at professional and nonprofessional health care workers. BIENNIAL REPORT, 
supra note 52, at 90. 
85. APED, supra note 20, at 7-8, paras. 29-34, cited in International Regulation, supra 
note 15, at 352. 
86. Two international organizations were quick to respond. The International Federa-
tion of Pharmaceutical Manufacturers Associations and the World Federation of Proprietary 
Medicine Manufacturers provided training for government-sponsored quality control techni-
cians. BIENNIAL REPORT, supra note 52, at 90. 
87. Some WHA members believed a "solution to the problem was more likely to be 
found at the level of the users rather than in an approach to those who sold drugs." World 
Health Organization, Official Records, No. 248, 423 (1978) (statement of Professor Koumare 
of Mali). Pharmaceutical companies have, however, supplied funds and personnel in an attempt 
to assist developing countries. International Regulation, supra note 15, at 352. 
88. InternaNonal Regulation, supra note 15, at 352. 
89. APED. aupra note 20, at 7-8, paras. 30-32, cited in International Regulation, supra 
note 15, at 352. 
90. International Regulation, supra note 15, at 352-53. 
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III. RECENT PROPOSALS FOR INTERNATIONAL 
REGULATION 
131 
Two recent proposals for WHO's direct involvement in inter-
national regulation are Scientific Evaluation Documents and an in-
ternational code of conduct for the marketing of pharmaceuticals.91 
A. SCIENTIFIC EVALUATION DOCUMENTS 
In 1981, the WHO European Regional Committee proposed the 
Scientific Evaluation Document (SED) system.92 The SED system 
would assist countries in their determination of whether or not to 
register a drug for domestic sale.93 
The SED system endorses the operation of an international 
drug evaluation agency.94 Pharmaceutical companies would provide 
the agency with all pertinent information regarding a drug. This 
information would include all chemical data, clinical studies, and 
medical information concerning correct use.95 After studying this 
information and determining that a drug meets proper quality, 
efficacy, and safety standards, the agency would issue a Scientific 
Evaluation Document.96 The existence of these documents would 
aid developing countries in deciding whether or not to purchase 
and import a drug for domestic sale.97 
The SED system, however, remains a proposal primarily 
because of opposition by the pharmaceutical industry.98 Phar-
maceutical companies fear that the SED system would constitute 
a type of supranational control which would impose insuperable 
regulatory barriers.99 
B. AN INTERNATIONAL CODE OF CONDUCT FOR THE MARKETING 
OF PHARMACEUTICALS 
In May 1978, WHA requested the Director-General to consider 
91. Id. at 353. 
92. WHO Regional Office for Europe, Consultation on an International Scheme for Drug 
Evaluation: Summary Report, No. lCP/DPM 003(8) Rev. l, 5927B (1981) [hereinafter cited 
as SED]. 
93. SED, supra note 92, at 2, cited in International Regulation, supra note 15, at 353. 
94. This agency would operate much like a national drug registration system. Id. 
95. Id. 
96. SED, supra note 92, at l, cited in International Regulation, supra note 15, at 353. 
97. SED, supra note 92, at 2, cited in International Regulation, supra note 15, at 353. 
98. International Regulations, supra note 15, at 354. 
99. Id. 
11
et al.: International Regulation of Pharmaceuticals: a Who International
Published by SURFACE, 1984
132 Syr. J. Int'l L. & Com. [Vol. 11:121 
"the development of a code of marketing practices, with special em-
phasis on pharmaceutical products essential for the populations of 
developing countries .... "100 Such a code of conduct, 101 if adopted 
and adhered to by member states and pharmaceutical manufac-
turers, could provide the best means yet for international regulation. 
The purpose of a code of conduct for pharmaceutical marketing 
would be the establishment of a standard of pharmaceutical 
marketing practices to promote drug quality, especially the quality 
of drugs needed by developing countries. The code would apply to 
the marketing of all drug products and the availability of informa-
tion concerning the use of these products. Code provisions would 
probably restrict the advertising and promotion of drug products, 
establish quality standards that the products must meet,1°2 and con-
trol packaging and labeling so that all product ingredients appear 
on labels. The code may provide that member states adopt national 
legislation or regulations to implement the code.103 The code may 
also provide that governments monitor the code's application and 
call upon nongovernmental organizations, 104 professional groups, 105 
and consumer groups to aid the governments.106 
100. W.H.A. Res. 31.32 3(6) (1978) 2 1983 HANDBOOK OF RESOLUTIONS, supa note 21, at 
112. 
101. A code of conduct is a "legal instrument embodying a set of principles and rules 
(norms) adopted by states that establish standards and limits for the behavior of international 
actors." Fatouros, On the Implementation of International Codes of Conduct: An Analysis of 
Future Experience, 30 AM. U.L. REV. 941, 943 (1981). 
102. The code may specify the quality standard to be used. For example, the Inter-
national Code of Marketing of Breastmilk Substitutes requires that infant formulas meet 
the standards of the Codex Alimentarius Commission, a sub-group of WHO. International 
Code of Marketing of Breastmilk Substitutes, Annex W.H.O. Doc. A34NR/15 art. 10.2. 
103. Fatouros, supra note 101, at 958. 
The International Code of Marketing of Breastmilk Substitutes provides for govern-
mental adoption of national legislation or regulations. International Code of Marketing of 
Breastmilk Substitutes, supra note 102, art. 11.1. 
104. For example, the International Federation of Pharmaceutical Manufacturers 
Association. This association assisted in the development of technical expertise in GMP in-
spections. World Health Organization, Official Records, No. 248, 425 (1978). 
105. For example, the International Pharmaceutical Federation which is made up of 
national pharmaceutical associations of over sixty countries representing about 300,000 phar-
macists. Id. at 435. 
106. The International Code of Marketing of Breastmilk Substitutes provides for the 
help of nongovernmental and professional organizations. International Code of Marketing 
of Breastmilk Substitutes, supra note 102, art. 11.4. 
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IV. AN INTERNATIONAL CODE OF CONDUCT FOR THE 
MARKETING OF PHARMACEUTICALS AS 
INTERNATIONAL LAW 
A. CODES OF CONDUCT AS CUSTOMARY INTERNATIONAL LAW 
1. Codes of Conduct 
International organizations have spent an enormous amount 
of time and energy drafting codes of conduct.107 Codes have recent-
ly become popular in the area of controlling multinational corpora-
tions (MNC's).108 This popularity stems from the realization that 
MNC's can affect national policies and possess a very rapid growth 
rate.109 There is also a general consensus that MNC's can frustrate 
national development strategies and escape national regulation.110 
Most important to the recent popularity of codes is the lack of 
equilibrium between developed and developing countries.111 
The lack of equilibrium between developed and developing 
countries has led to diverging views on the legal effect of codes 
of conduct.112 The developed countries, including the United States, 
favor nonbinding or voluntary codes, which serve merely as 
guidelines for states and MNC's.113 They argue that nonbinding codes 
help to standardize national policies,114 that MNC's on their own in-
itiative cooperate with the standards set forth in the codes,115 and 
that voluntary codes help equalize the bargaining power between 
developing countries and MNC's.116 Developing countries, on the 
107. Rubin, Transnational Corporations and International Codes of Conduct: A Study 
of the Relationship Between International Legal Cooperation and Economic Development, 30 
AM. U.L. REV. 903, 907 (1981). 
For a discussion of recently adopted international codes of conduct affecting MNC's, 
see Vagts, Multinational Corporations and International Guidelines, 18 COMMON MKT. L. REV. 
463 (1981); Fikentscher, United Nations Codes of Conduct: New Paths in International Law, 
30 AM. J. COMP. L. 577 (1982). 
108. Rubin, supra note 107, at 907. 
109. Id. 
110. Id. at 907-08. 
111. Id. at 908. 
112. Stanley, supra note 2, at 981-82; Fatouros, supra note 101, at 949; Davidow & Chiles, 
The United States and the Issue of the Binding or Voluntary Nature of International Codes 
of Conduct Regarding Restrictive Business Practices, 72 AM. J. lNT'L L. 247, 249 (1978). 
113. Stanley, supra note 2, at 981. 
114. Coonrod, The United Nations Code of Conduct for Transnational Corporations, 18 
HARV. lNT'L L.J. 273, 303 (1977). 
115. Id. at 304. 
116. Id. at 305. 
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other hand, do not believe that "guideline" codes alter the behavior 
of MNC's.117 They, therefore, support legally binding codes.118 A bind-
ing code takes on the status of a treaty119 because it obligates its 
signatories to implement the code through national legislation.120 
2. Codes as Customary International Law 
A code of conduct can become customary international law121 
117. Davidow & Chiles, supra note 112, at 256. 
Developing countries also view themselves as powerless against the MNC's within their 
borders. Id. 
118. Id. at 257. 
119. A treaty is an instrument which is "concluded among a number of countries acting 
in their joint interest .... [A] treaty is obligatory originally only on such states as signed 
and ratified it." G. VON GLAHN. LAW AMONG NATIONS 17 (4th ed. 1981). 
120. Stanley, supra note 2, at 982. 
Many interesting alternatives have been suggested to alleviate the tension between 
developing and developed countries on the legal effect of codes of conduct. One such alter-
native is the "zebra code" in which some provisions are adopted in a binding form while 
others are adopted in a nonbinding form. Fatouros, supra note 101, at 950. Other alternatives 
include: international arbitration, international consultation, norm refinement, and follow-
up procedures. Davidow & Chiles, supra note 112, at 263-70. 
121. Article 38(1) of the Statute of the International Court of Justice, which sets forth 
the sources of international law, provides: 
the Court, whose function is to decide in accordance with international law such 
disputes as are submitted to it, shall apply: 
a. international conventions, whether general or particular, establishing rules 
expressly recognized by the contesting states; 
b. international custom, as evidence of a general practice accepted as law; 
c. the general principles of law recognized by civilized nations; 
d. subject to the provisions of Article 59, judicial decisions and the teachings 
of the most highly qualified publicists of the various nations, as subsidiary means 
for the determination of rules of law. 
Stat. I.C.J. art. 38(1), reprinted in DOCUMENTS ON THE INTERNATIONAL COURT OF JUSTICE 79 
(S. Rosenne 2d ed. 1979). 
Article 38(1)(b) contains two consecutive elements of customary international law:" '(1) 
a general practice of states and (2) the acceptance by states of the general practice as law.'" 
H. THIRLWAY, ITERNATIONAL CUSTOMARY LAW AND CODIFICATION 46(1972), citingG. SCHWARZEN-
BERGER, A MANUAL OF INTERNATIONAL LAW 32 (1967). 
Customary international law has three weaknesses which have caused the international 
treaty to move to the forefront as a source of international law. VON GLAHN, supra note 119, 
at 23. First, the formulation of customary law is a slow process. After the lengthy process 
of formulation and recognition, a new customary rule may actually be archaic and outdated. 
Id. 
Second, the process can be unfair to a newly originated state. Id. A state is not bound 
by a customary rule if it objected to the rule during the formulation process, but a new 
state is bound by all customary international law at the time the new state originates. Id. 
Third, evidence of custom may be very difficult to piece together. Any act or declara-
tion of a state may be evidence of custom. J. BRIERLY, THE LAW OF NATIONS 60 (6th ed.1963). 
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if it meets the requirements of state practice122 and opinio juris. 123 
States may modify their practices to conform with even voluntary 
code provisions124 and may police the actions of MNC's within and 
without their borders to ensure compliance with code provisions.125 
These state actions can constitute state practice, one necessary ele-
ment of customary international law.126 States may further view 
their compliance with code provisions. as obligatory, so that they 
expect punishment or sanctions to result from their deviation from 
provisions.121 Their belief that code provisions are obligatory can 
122. The material element in the formulation of customary law is the requirement of 
general practice or usage. THIRLWAY, supra note 121, at 56. The practice or usage must be 
followed sufficiently and consistently by a number of states. "Practice or usage consists 
of an accumulation of acts which are material or concrete in the sense that they are intended 
to have an immediate effect on the legal relationships of the State concerned ... . "Id. at 58-59. 
123. "Opinio juris sive necessitatis" is translated as "understanding of the law of 
necessity." CASSELL'S LATIN DICTIONARY (5th ed. 1968). 
Opinio juris, the acceptance by states of the general practice as law, is the second ele-
ment in the formulation of customary law. Stat. l.C.J., supra note 121, art. 38(1)(b). States 
must generally recognize the practice as obligatory, so that a deviation from the practice 
entails the possibility of punishment or sanction. BRIERLY, supra note 121, at 59. 
International legal authorities, however, possess differing views on the definition of 
opinio juris. For a discussion of these differing views, see THIRLWAY, supra note 121, at 47-56; 
Note, Formulating Customary International Law: An Examination of the WHO International 
Code of Marketing of Breastmilk Suhstitutes, 5 B.C. INT'L & COMP. L. REV. 377, 397-98 (1982) 
[hereinafter cited as Formulating Customary International Law]. 
One authority, D'Amato, has attempted to reformulate the entire theory of customary 
law. He has proposed the abolishment of practice and opinio juris and has substituted in 
their places an "act or commitment" and "articulation." A. D'AMATO, THE CONCEPT OF CUSTOM 
IN INTERNATIONAL LAW 73-87 (1971). 
124. Davidow & Chiles, supra note 112, at 255. 
125. Formulating Customary International Law, supra note 123, at 399. 
126. See supra note 122. 
Some scholars, however, doubt that customary international law can be developed in 
international organizations. 0. ASAMOAH, THE LEGAL SIGNIFICANCE OF THE DECLARATIONS OF 
THE GENERAL ASSEMBLY OF THE UNITED NATIONS 52 (1966). They argue that resolutions and 
recommendations of international organizations are not evidence of state practice because: 
(1) it is difficult to determine when this practice becomes law, (2) the independent practice 
of states is confused with the acts of the organization, and (3) resolutions are not formal 
practice within the meaning of article 38. Id. 
Because only state actions can qualify as state practice, it has been argued that the 
behavior of MNC's cannot contribute to the formulation of customary law. See Formulating 
Customary International Law, supra note 123, at 398. Nevertheless, states which police the 
actions of MNC's to insure compliance with code provisions can provide sufficient state prac-
tice for the formulation of customary law. Id. at 398-99. 
127. Davidow & Chiles, supra note 112, at 255. 
A state which departs from code provisions may be subject to the pressure or moral 
persuasion of other states. This subjection to pressure or persuasion would amount to sanc-
tion. Id. 
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constitute opinio juris, the second necessary element in the formula-
tion of customary international law.128 Even a nonbinding code, 
therefore, can become customary international law when sufficient 
state practice and opinio juris are present.129 An example of a re-
cent non binding code, which can become customary law, is the Inter-
national Code of Marketing of Breastmilk Substitutes.130 
B. INTERNATIONAL CODE OF MARKETING OF BREASTMILK 
SUBSTITUTES-AN EXAMPLE OF A RECENT WHO CODE OF 
CONDUCT 
In May 1981, WHA adopted the International Code of 
Marketing of Breastmilk Substitutes (Code of Breastmilk 
Substitutes).131 The Code's purpose is to stress the superiority of 
breastfeeding over bottle feeding,1 32 especially in developing 
128. See supra note 123. 
129. Davidow & Chiles, supra note 112, at 255. 
130. International Code of Marketing of Breastmilk Substitutes, Annex W.H.O. Doc. 
A34NR/15 [hereinafter cited as Code of Breastmilk Substitutes]. 
131. W.H.A. Res. 34.22 (1981) 2 1983 HANDBOOK OF RESOLUTIONS, supra note 21, at 78; 
Code of Breastmilk Substitutes, supra note 130. 
A joint WHO/UNICEF Meeting on Infant and Young Child Feeding held in October 
1979 recommended "an international code of marketing of infant formula and other products 
used as breastmilk substitutes." W.H.A. Res. 33.32(1) (1980) 2 1983 HANDBOOK OF RESOLU-
TIONS, supra note 21, at 76. In May 1980, WHA requested the Director-General to prepare, in 
collaboration with experts, an international code of marketing of breastmilk substitutes. 
W.H.A. Res. 33.32(6(4)) (1980) id. WHA further requested the Director-General to submit 
the Code to the Executive Board and WHA with proposals for implementation either as 
a regulation or recommendation. W.H.A. Res. 33.32(6(5)) (1980) id. In January 1981, the 
Executive Board endorsed the Draft International Code, and in May 1981, WHA adopted 
the Code as a recommendation. E.B. Res. 67.R12(1) (1981) id. at 77; W.H.A. Res. 34.22(1) (1981) 
id. at 78. 
132. Animal milks were not recognized as an alternative to mother's milk until quite 
recently. In the 1880's, scientists modified cow's milk to provide digestible infant formulas. 
World Health Organization, CONTEMPORARY PATTERNS OF BREAST-FEEDING-REPORT ON THE 
WHO COLLABORATIVE STUDY ON BREAST-FEEDING 3 (1981). In the 1930's, the food industry 
began preparation of formulas which before had been processed at home. Id. at 4. Breastmilk 
substitutes became more widespread and are now used routinely in developing countries. 
Id. Problems in these developing countries have, however, caused infant formulas to have 
a detrimental effect on infant health. These problems include: poor sanitation and water 
supply, inadequate facilities for proper cleaning of bottles, and a poor economic situation 
in which the high cost of formula leads to overdilution. Id. 
Studies in the United States and abroad showed that the mortality rate for bottle-fed 
infants was two to six times that for breast-fed infants in the 1930's. Id. at 4-5. 
In the 1960's, authorities questioned the decline in breastfeeding and developed 
arguments in favor of its revival. Id. at 6. They argued that breastfeeding creates a bond 
between mother and child, that manufactured formulas can never copy the anti-infective 
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countries.133 The Code restricts manufacturers of breastmilk 
substitutes in their direct advertising to the general public, 134 in 
their provision of free samples to the general public, 135 and in their 
provision of information to health professionals.136 The Code also 
calls upon governments to adopt the Code as national legislation.137 
The Code of Breastmilk Substitutes is the result of WHO's first 
attempt to deal with a public health problem by controlling the 
marketing practices of MNC's.138 Despite WHA's adoption of the 
Code as a voluntary recommendation,139 the United States voted 
against its adoption.140 Manufacturers of infant formula have also 
opposed the Code. One such manufacturer believes that certain ar-
ticles of the Code have no connection with infant health,141 that the 
Code sets a distasteful precedent for supranational legislation, 142 
and that the Code is not applicable to developed countries, including 
the United States.143 In May 1982, WHA, after noting that few 
member states had adopted and adhered to the Code, again urged 
properties of human milk, and that breastfeeding is a child's only fair chance at survival 
in low income and poorly educated populations. Id. 
Since the 1960's, various international organizations have worked to promote 
breastfeeding in developing countries. Some of these organizations are: the La Leche League 
International, the Protein-Calorie Advisory Group of the United Nations System, the In-
ternational Pediatric Association, the International Union of Nutritional Sciences, and the 
International Planned Parenthood Federation. Id. at 6-8. 
133. W.H.A. Res. 33.32(4Kb) (1980) 2 1983 HANDBOOK OF RESOLUTIONS, supra note 21, at 77. 
WHA discovered that the decline in breastfeeding contributes "to infant mortality and 
malnutrition, in particular in the developing world .... " W.H.A. Res. 27.43 (1974) id. at 76. 
134. Code of Breastmilk Substitutes, supra note 130, art. 5.1. 
135. Id. art. 5.2. 
136. Id. art. 7.2. 
137. Id. art. 11.1. 
138. See Formulating Customary International Law, supra note 123, at 386. 
For additional information on the control of multinational infant formula corporations, 
see Note, Influencing Multinational Corporations: The Infant Formula Marketing Controversy, 
10 N.Y.U.J. INT'L L. & POL. 125 (1977). 
139. "The Thirty-four World Health Assembly ... ADOPTS, in the sense of Article 
23 of the Constitution, the International Code of Marketing of Breastmilk Substitutes . 
. . . " W.H.A. Res. 34.22(1) (1981) 2 1983 HANDBOOK OF RESOLUTIONS, supra note 21, at 78. 
140. See Formulating Customary International Law, supra note 123, at 382. 
For a discussion of U.S. action prior to the WHO Code of Breastmilk Substitutes, see 
Note, Innocents Abroad: Infant Food Technology at the Law's Frontier, 20 VA. J. INT'L L. 617 
(1980). 
141. Company Agrees to WHO Code in Developing Nations, Bristol-Myers USA, Sept. 
1983, at 4, col. 1. 
142. Id. 
143. Id. 
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member states to "adopt national legislation, regulations or other 
suitable measures to give effect to the International Code .... "144 
As of June 17, 1983, however, only one American manufacturer of 
infant formula has agreed to comply with the Code.145 
C. THE POSSIBLE ADOPTION AND LEGAL EFFECT OF AN 
INTERNATIONAL CODE OF CONDUCT FOR THE MARKETING OF 
PHARMACEUTICALS 
WHO's first attempt to promote health in developing countries 
by controlling the marketing practices of MNC's has been met with 
opposition, especially by the MNC's themselves.146 Unless this op-
position gradually evaporates, WHO may be reluctant to proceed 
with a code that would control the marketing practices of MNC's 
that manufacture pharmaceuticals. WHO may view the Code of 
Breastmilk Substitutes as a failure, and, therefore, be hesitant to 
draft another code that may fail. The adoption of an international 
code of marketing for pharmaceuticals is unlikely, in the near future, 
because of state and MNC opposition and the length of time required 
to draft a satisfactory code of conduct. 
If, however, WHO were to develop and adopt such a code of 
conduct, it would probably take the form of a nonbinding 
recommendation.147 Recommendations do not require the elaborate 
approval procedures of binding instruments.148 Additionally, states 
144. W.H.A. Res. 35.26 (1982) 2 1983 HANDBOOK OF RESOLUTIONS, supra note 21, at 79. 
145. Despite its reservations about the Code, Bristol-Myers, on June 17, 1983, announced 
its decision to comply with the Code. Bristol-Myers USA, supra note 141, at 4, cols. l, 3. 
Secretary of Health and Human Services, Margaret M. Heckler, has recently commended 
Bristol-Myers on its decision to comply with the Code. Secretary Heckler stated that Bristol-
Myers' decision "will help considerably in ending the controversy surrounding the Code 
and in allowing various involved groups to work toward improving the health of infants 
and young children." Company's WHO Code Policy Wins Praise, Bristol-Myers USA, Jan. 
1984, at 3, cols. l, 2 (statement of Secretary Margaret M. Heckler). 
A Bristol-Myers' official voiced the company's continuing concern that "certain sections 
of the Code are inappropriate to countries like the U.S. and other developed nations." Id. 
at 3, cols. 2, 3 (statement of Marvin Koslow, Senior Vice-President of Bristol-Myers). Secretary 
Heckler's response was that "many of the Code's provisions ... are considered inappropriate 
here because our social and economic circumstances are different from those in the developing 
nations, which were the primary target of the Code." Id. at 3, col. 3 (statement of Secretary 
Margaret M. Heckler). 
Senator Edward Kennedy, who, in 1978, conducted hearings on the marketing of in-
fant formula in developing countries, also commended Bristol-Myers on its compliance with 
the Code. Id. at 3, col. 4. 
146. See supra notes 141-144 and accompanying text. 
147. See supra notes 45-46 and accompanying text. 
148. See Formulating Customary International Law, supra note 123, at 390. See also 
supra note 45. 
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appear to be more willing to adopt nonbinding instruments.149 The 
voluntary Code of Breastmilk Substitutes has even been opposed 
by infant formula manufacturers based in those developed coun-
tries that favor nonbinding instruments.150 
The likelihood of an international code for the marketing of 
pharmaceuticals becoming customary international law is even more 
speculative. The formulation of customary international law is a 
slow process.151 If a number of countries comply with the code and 
require their pharmaceutical industries to also comply, state prac-
tice could exist.152 If states come to view the code as obligatory, 
so that noncomplying states would feel pressure to also comply, 
sufficient opinio juris could exist.153 Both state practice and opinio 
juris require the participation of a substantial number of states.154 
Because the Code of Breastmilk Substitutes has, as of yet, not ob-
tained substantial compliance, a similar code for pharmaceuticals 
would also probably not receive substantial compliance to become 
customary international law. Thus, both time and the noncompliance 
of states would hinder a code of conduct for the marketing of phar-
maceuticals from acquiring the status of international law. 
Although a voluntary code may not achieve the status of 
customary law, it may still be a valuable tool in the international 
pharmaceutical trade.155 Pharmaceutical MNC's, while not comply-
ing with the entire code, may employ certain code provisions and 
policies in establishing or changing their own marketing practices. 
The code could certainly serve as a model for those MNC's that 
"want to demonstrate ... awareness that there are differences be-
tween the developing and developed world to which ethical 
marketers must be sensitive."156 
D. A SUGGESTED SOLUTION FOR LESS DEVELOPED COUNTRIES 
The WHO regulatory programs157 and proposals158 fail to supply 
less developed countries (LDC's) with adequate relief from the im-
149. See Formulating Customary International Law, supra note 123, at 391. 
150. See supra notes 113-116 and accompanying text. 
151. VON GLAHN, supra note 119, at 23. 
152. See Formulating Customary International Law, supra note 123, at 399. 
153. Davidow & Chiles, supra note 112, at 255. 
154. THIRLWAY, supra note 121, at 58. 
155. Fatouros, supra note 101, at 959. 
156. Bristol-Myers USA, supra note 141, at 4, cols. 1-2. 
157. See supra notes 21-90 and accompanying text. 
158. See supra notes 92-106 and accompanying text. 
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portation of defective drug products.159 Additionally, not all LDC's 
can afford either the funds or the manpower to establish their own 
elaborate regulatory schemes.160 LDC's should, therefore, pool what 
little resources they have and coordinate their efforts at regula-
tion. These LDC's, in a collaborative effort, should develop and im-
plement a comprehensive product liability law161 that makes foreign 
manufacturers more strictly accountable for drug-related injuries.162 
This comprehensive product liability law should encourage the 
importation of goods into LDC's as well as promote the protection 
of users.163 It should introduce the theory of strict liability164 to 
LDC's165 and grant LDC courts jurisdiction over foreign manufac-
turers in transnational product liability suits.166 
159. See supra notes 21-106 and accompanying text. 
160. Note, Influencing Multinational Corporations: The Infant Formula Marketing Con-
troversy, 10 N.Y.U.J. INT'L L. & POL. 125, 163 (1977). 
For example, few governments of developing countries regulated infant formulas before 
the development of the Code of Breastmilk Substitutes. Note, Innocents Abroad: Infant Food 
Technology at the Law's Frontier, 20 VA. J. INT'L L. 617, 638 (1980). 
161. Product liability law concerns the "legal liability of manufacturers and sellers to 
compensate buyers, users, and even bystanders, for damages or injuries suffered because 
of defects in goods purchased." BLACK'S LA w DICTIONARY 1089 (5th ed. 1979). 
162. An example of a product liability law which makes foreign manufacturers more 
strictly accountable for product-related injuries is the recently proposed directive of the 
European Economic Community (EEC). Amendment of the Proposal for a Council Directive 
Relating to the Approximation of the Laws, Regulations and Administrative Provisions of 
the Member States Concerning Liability for Defective Products, 22 O.J. EUR. COMM. (No. 
C271) 3 (1979) [hereinafter cited as EEC Directive]. 
163. The EEC Directive contains a similar objective and seeks to accomplish its objec-
tive by creating general obligations for all manufacturers of defective products and impos-
ing liability without fault to facilitate recovery of damages for consumers. Recent Develop-
ment, The EEC's Proposed Directive un Products Liability: A Call for Reappraisal in Light 
of the Model Uniform Product L iabilitu Act, 6 B.C. INT'L & COMP. L. REV. 315, 320-21 (1983). 
164. Strict liability is a "concept applied by the courts in product liability cases in which 
a seller is liable for any and all defective or hazardous products which unduly threaten a 
consumer's personal safety." BLACK'S LAW DICTIONARY 1275 (5th ed. 1979). 
165. The EEC Directive imposes strict liability on manufacturers: "[t]he producer of 
an article shall be liable for damage caused by a defect ... [t]he producer shall be liable 
even if the article could not have been regarded as defective in light of the scientific and 
technological development at the time when he put the article into circulation." EEC Direc-
tive, supra note 162, at 7-8. 
166. The EEC Directive facilitates a consumer in obtaining jurisdiction over the pro-
ducer within the EEC. Recent Development, supra note 163, at 330. 
Jurisdiction over pharmaceutical MNC's may not, however, be a problem because states, 
ii' civil trials, "claim jurisdiction over all sorts of cases and parties having no real connec-
tion with them and ... this practice has seldom if ever given rise to diplomatic protests." 
Akehurst, Jurisdiction in International Law, 46 BRIT. Y.B. INT'L L. 145, 170 (1972-1973). 
The main basis of jurisdiction in common law countries is the defendant's presence within 
the state. Id. A company is present within the state if it conducts business in the state even 
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Although this suggested solution may also pose problems, 167 
it does reflect the growing feeling among LDC's that "transfer of 
technology disputes are exclusively within the jurisdiction of the 
[LDC's)."168 
V. CONCLUSION 
The ongoing debate between developed and developing coun-
tries concerning the legal effect of codes prevents the adoption of 
codes that affect the marketing practices of MNC's. It seems ap-
parent that until this debate is resolved and countries realize the 
advantageous aspects of codes, the development of a code for the 
marketing of pharmaceuticals is unlikely. After considerable time, 
a code could become customary international law and, as such, bind 
even those countries and their MNC's that initially object. Further-
more, ·a code of conduct would do much to standardize the marketing 
of pharmaceuticals and protect developing countries from the im-
portation of defective products. 
While the debate over the legal effect of codes continues and 
the development of a code of conduct for the marketing of phar-
maceuticals in unlikely, developing countries can protect themselves 
from defective drug products by expanding their product liability 
law. In order to protect and compensate drug product users, this 
law should include the theory of strict liability and allow drug users 
jurisdiction over foreign pharmaceutical manufacturers. 
M olinda Schoepe 
if the business is brief and not connected with the subject matter of the litigation. Id. at 
170 n.5. 
Some countries claim jurisdiction whenever the defendant has assets within the coun-
try concerned. Id. at 171. 
Some foreign courts have jurisdiction based on the plaintiffs nationality, domicile, or 
residence. Id. at 172-73. 
167. Some problems may include: manufacturers' refusals to do business with these 
LDC's, an increase in the cost of insuring products, and increased consumer prices to cover 
the cost of damages and insurance payments. 
168. Report of the Intergovernmental Experts on an International Code of Conduct 
on Transfer of Technology on its Fourth Session, U.N. Doc. TD/AC.1/11, Annex 11 (Nov. 
23, 1977), reprinted in 17 l.L.M. 453, 472-73 (1978). 
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